Q4 2025 Merck & Co Inc Earnings Call Transcript

Feb 3, 2026 / 02:00 PM GMT

Release Date Price: $115.84 (+2.18%)

Transcript 8-K

Key Points

Positve

Merck & Co Inc (MRK) reported strong growth in 2025, driven by successful new product launches and advancements in clinical programs.
The company has a potential commercial opportunity of over $70 billion by the mid-2030s, significantly higher than previous estimates.
Keytruda continues to show robust uptake in earlier stage cancers and strong demand for metastatic indications, contributing to oncology growth.
Merck & Co Inc (MRK) completed strategic acquisitions, such as Verona Pharma and Cedara Therapeutics, to expand its respiratory and infectious disease portfolios.
The company is making significant clinical advancements, with multiple product launches and a robust pipeline expected to drive long-term growth.

Negative

Gardasil sales decreased by 35% due to lower demand in China and Japan, impacting overall vaccine sales.
The company faces a headwind of approximately $2.5 billion from generic competition and IRA price setting.
Merck & Co Inc (MRK) expects significantly lower sales of Legevrio due to continued soft demand.
Operating expenses are projected to be high, including a one-time charge of approximately $9 billion related to the acquisition of Sierra.
The company anticipates minimal top-line growth in 2026, with challenges such as generic competition and restructuring agreements impacting revenue.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MRK.N - Merck & Co Inc
Q4 2025 Merck & Co Inc Earnings Call
Feb 03, 2026 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by. Welcome to the Merk and Company Inc. Rahway, New Jersey, USA 4th quarter sales and earnings conference call. At this time, all participants are in a listen-only mode until the question-and-answer session of today's conference.

At that time, if you'd like to ask a question, you may press 1 on your phone and record your name at the prompt. Disconnect at this time.

I would now like to turn the conference over to Mr. Peter Danbam, senior Vice President of Investor relations. Sir, you may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.